You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

donor lymphocyte infusions

Showing 1 - 25 of 5,626
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hematologic Malignancy Trial in Tuebingen,, Tuebingen (CD45RA depleted donor lymphocyte infusion (DLI))

Recruiting
  • Hematologic Malignancy
  • CD45RA depleted donor lymphocyte infusion (DLI)
  • Tuebingen,, Germany
  • +1 more
Jul 13, 2023

Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor Trial in Miami (T-cell Receptor a/ß Depleted Donor Lymphocyte

Recruiting
  • Lymphoid Leukemia, Acute
  • +2 more
  • T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc
May 24, 2022

MDS, AML Trial in France (ASTX727, Donor Lymphocyte Infusions)

Recruiting
  • MDS
  • AML
  • Amiens, France
  • +15 more
Jul 21, 2022

Severe Combined Immunodeficiency Trial in Memphis (drug, device, other)

Recruiting
  • Severe Combined Immunodeficiency
  • Anti-thymocyte globulin (rabbit)
  • +5 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Oct 6, 2021

Hematologic Malignancy Trial in Saint Petersburg (Prophylactic Donor lymphocytes infusions, Preventive Donor lymphocytes

Recruiting
  • Hematologic Malignancy
  • Prophylactic Donor lymphocytes infusions
  • Preventive Donor lymphocytes infusions
  • Saint Petersburg, Russian Federation
    RM Gorbacheva Research Institute
Aug 16, 2021

Tumor Metastasis Trial run by the NHLBI (methotrexate, Cyclosporin)

Terminated
Has Results
  • Neoplasm Metastasis
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Nov 8, 2021

Multiple Myeloma Trial in New York (busulfan, melphalan and fludarabine)

Completed
Has Results
  • Multiple Myeloma
  • busulfan, melphalan and fludarabine
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 4, 2021

Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, Leukemia, Myelocytic, Chronic Trial run by the NHLBI (Miltenyi

Completed
Has Results
  • Leukemia, Myeloid, Acute
  • +2 more
  • Miltenyi Magnetic cell sorter for CD3
  • Bethesda, Maryland
    National Institutes of Health
Oct 7, 2020

Hematologic Malignancy, Haplo-identical Stem Cell Transplantation Trial (CD45RAneg cells, prepared from mononuclear cell

Not yet recruiting
  • Hematologic Malignancy
  • Haplo-identical Stem Cell Transplantation
  • CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology
  • (no location specified)
Oct 1, 2021

Hematologic Tumors Trial run by the NCI (donor lymphocyte infusion, Cyclophosphamide, Busulfan)

Suspended
  • Hematologic Neoplasms
  • donor lymphocyte infusion
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Nov 30, 2022

Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Recurrent Adult Acute Myeloid

Completed
  • Minimal Residual Disease
  • +3 more
  • Daratumumab
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 2, 2022

Hematopoietic Organs; Disorder Trial in Hong Kong (CD62L depleted donor lymphocyte infusion)

Recruiting
  • Hematopoietic Organs; Disorder
  • CD62L depleted donor lymphocyte infusion
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
Sep 6, 2023

Leukemia, Myeloid, Acute, MDS, Leukemia, Myelomonocytic, Chronic Trial in Duesseldorf (Lenalidomide, Azacitidine, Donor

Completed
  • Leukemia, Myeloid, Acute
  • +2 more
  • Duesseldorf, NRW, Germany
    University Hospital Duesseldorf, Dept. of Hematology, Oncology a
May 26, 2020

AML/MDS Trial in Copenhagen (iDLI)

Recruiting
  • AML/MDS
  • iDLI
  • Copenhagen, Denmark
    Copenhagen University Hospital, Rigshospitalet
Jan 13, 2023

Acute Lymphocytic Leukemia Trial in Philadelphia (CART-19)

Terminated
  • Acute Lymphocytic Leukemia
  • CART-19
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jul 7, 2020

Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)

Active, not recruiting
  • Relapsed Adult ALL
  • Relapsed Adult AML
  • Changchun, Jilin, China
    First Hospital of Jilin University
Nov 19, 2023

Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)

Withdrawn
  • Leukemia
  • Stem Cell Transplantation
  • Munich, Bavaria, Germany
    3. Medizinische Klinik, Klinikum rechts der Isar der TU München
Dec 5, 2022

Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Tumor Trial in Buffalo (donor lymphocytes)

Completed
Has Results
  • Leukemia
  • +3 more
  • donor lymphocytes
  • Buffalo, New York
    Roswell Park Cancer Institute
Aug 21, 2020

Solid Tumor Malignancies Trial in Houston (Autologous lymphocyte infusion (ALI))

Recruiting
  • Solid Tumor Malignancies
  • Autologous lymphocyte infusion (ALI)
  • Houston, Texas
    M D Anderson Cancer Center
Jul 14, 2022

Immunodeficiency Trial in Charlotte (Infusion of donor lymphocytes)

Terminated
Has Results
  • Immunodeficiency
  • Infusion of donor lymphocytes
  • Charlotte, North Carolina
    Levine Children's Hospital, Carolinas Medical Center
Apr 20, 2022

Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)

Recruiting
  • Myeloid Malignancies
  • Lymphoid Malignancies
  • NK Cell enriched-DLI only
  • NK-DLI + DUK-CPG-001
  • Durham, North Carolina
    Duke University Health System
Mar 8, 2022

Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation Trial (Siremadlin)

Recruiting
  • Acute Myeloid Leukemia
  • Allogeneic Stem Cell Transplantation
  • Tel Aviv, Israel
  • +2 more
Jan 23, 2023

Relapsed Neuroblastoma, Refractory Neuroblastoma Trial (Natural Killer Cells, Temozolomide, Irinotecan)

Recruiting
  • Relapsed Neuroblastoma
  • Refractory Neuroblastoma
  • Natural Killer Cells
  • +4 more
  • Columbus, Ohio
    Nationwide Children's Hospital
Oct 26, 2022

MDS, Leukemia, Myeloid, Acute Trial in London (DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell

Unknown status
  • Myelodysplastic Syndromes
  • Leukemia, Myeloid, Acute
  • DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)
  • DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice
  • London, United Kingdom
    King's College Hospital NHS Foundation Trust
Apr 1, 2020

Acute Myeloid Leukemia, in Relapse Trial in Freiburg (Bicanorm)

Completed
  • Acute Myeloid Leukemia, in Relapse
  • Freiburg, Baden-Württemberg, Germany
    Medical Center University of Freiburg
Mar 24, 2020